| Zacks Company Profile for Capricor Therapeutics, Inc. (CAPR : NSDQ) |
|
|
| |
| • Company Description |
| Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California.
Number of Employees: 160 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $6.34 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 2,021,592 shares |
| Shares Outstanding: 45.68 (millions) |
| Market Capitalization: $289.59 (millions) |
| Beta: 0.85 |
| 52 Week High: $23.40 |
| 52 Week Low: $3.52 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-28.60% |
-33.55% |
| 12 Week |
-59.23% |
-55.95% |
| Year To Date |
-54.06% |
-47.55% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
10865 Road to the Cure Suite 150
-
San Diego,CA 92121
USA |
ph: 858-727-1755
fax: 415-875-7075 |
info@capricor.com |
http://www.capricor.com |
|
|
| |
| • General Corporate Information |
Officers
Linda Marban - Chief Executive Officer;President and Director
Frank Litvack - Executive Chairman and Director
Anthony J. Bergmann - Chief Financial Officer
Earl M. Collier - Director
David B. Musket - Director
|
|
Peer Information
Capricor Therapeutics, Inc. (BJCT)
Capricor Therapeutics, Inc. (CADMQ)
Capricor Therapeutics, Inc. (APNO)
Capricor Therapeutics, Inc. (UPDC)
Capricor Therapeutics, Inc. (IMTIQ)
Capricor Therapeutics, Inc. (CYGN)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 14070B309
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 05/13/25
|
|
Share - Related Items
Shares Outstanding: 45.68
Most Recent Split Date: 6.00 (0.10:1)
Beta: 0.85
Market Capitalization: $289.59 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.36 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.42 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 5.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 05/13/25 |
|
|
|
| |
